Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Controversies in Nephrology
You have accessRestricted Access

Influence of Industry on Renal Guideline Development

Daniel W. Coyne
CJASN January 2007, 2 (1) 3-7; DOI: https://doi.org/10.2215/CJN.02170606
Daniel W. Coyne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

There is ongoing controversy concerning the influence of the pharmaceutical industry on physicians, research publications, medical societies, and disease advocacy groups (1–7). Nowhere is the potential influence of industry more concerning than in development of clinical practice guidelines (8), which are designed to improve and standardize patient care yet also have enormous economic implications. As outlined herein, industry has provided major financial support to the National Kidney Foundation (NKF), the principal organization that develops and promulgates management guidelines in nephrology, and honoraria and/or research support to many participants who are involved in nephrology guideline development. Opinion-based recommendations have benefited some industries and harmed others. If not managed appropriately, then these relationships have the opportunity to undermine the guidelines and harm industry’s reputation. They also may reflect poorly on the renal community in general and threaten our independence. Major changes are necessary to limit the influence of conflicts of interest and the appearance of undue influence. The recent 2006 Kidney and Dialysis Outcomes Quality Initiative (KDOQI) anemia guidelines highlight many of these issues.

The New Hemoglobin Target

The recent 2006 KDOQI anemia guidelines increased the target hemoglobin range from 11 to 12 to 11 to 13 g/dl for all patients with chronic kidney disease (CKD) (9). Because of the tight relationship in patients with CKD between target hemoglobin and erythropoietin-stimulating protein (ESP; epoetin or darbepoetin) dosage (Figure 1), this undoubtedly will increase ESP use and cost to the health care system.

Figure 1.

US hemodialysis prevalent patient mean weekly epoetin dosage (dashed line) and hemoglobin (solid line) from 1993 to 2004. Rate of deaths per 1000 patient-years (–•–) in prevalent US hemodialysis patients, adjusted for age, gender, race, and primary renal disease. Adapted from reference (10), pp 16, 26.

Since 1991, the mean hemoglobin and mean epoetin dosage in dialysis patients have risen steadily. Medicare’s …

View Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 2, Issue 1
January 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Influence of Industry on Renal Guideline Development
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Influence of Industry on Renal Guideline Development
Daniel W. Coyne
CJASN Jan 2007, 2 (1) 3-7; DOI: 10.2215/CJN.02170606

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Influence of Industry on Renal Guideline Development
Daniel W. Coyne
CJASN Jan 2007, 2 (1) 3-7; DOI: 10.2215/CJN.02170606
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • The New Hemoglobin Target
    • NKF, KDOQI, and COI
    • KDOQI Structure and Procedures and the Impact on Guideline Development
    • Kidney Disease Improving Global Outcomes, Pharmaceutical Support, and the Appearance of Bias
    • Recommendations
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro
  • Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Introduction
  • Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con
Show more Controversies in Nephrology

Cited By...

  • ESRD Databases, Public Policy, and Quality of Care: Translational Medicine and Nephrology
  • The Need to Systematically Evaluate Clinical Practice Guidelines
  • Suggestions for improving guideline utility and trustworthiness
  • Standardized Clinical Assessment And Management Plans (SCAMPs) Provide A Better Alternative To Clinical Practice Guidelines
  • Funding for Medical Education: Maintaining a Healthy Separation From Industry
  • Invited Article: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines
  • Battleground: Chronic Kidney Disorders Mineral and Bone Disease Calcium Obsession, Vitamin D, and Binder Confusion
  • Value of Quality Improvement Reporting
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire